435 assets in Melanoma

Therapeutic assets addressing Melanoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Fosifloxuridine Nafalbenamide Melanoma	NuCana plc	P1/2	C (35)
Ex-Vivo Expanded Allogeneic Γδ T Cells Melanoma	Xijing Hospital	Early P1	C (34)
R130 Melanoma	Shanghai Yunying Medical Technology	Early P1	C (34)
Recombinant L-Ifn Adenovirus Melanoma	Shanghai Fengxian District Central Hospital	Early P1	C (34)
ltt462 Melanoma	Novartis Pharmaceuticals	P2	C (33)
Incb 086550 Melanoma	Incyte Corporation	P2	C (32)
Mb-Cart19.1 Melanoma	Miltenyi Biomedicine GmbH	N/A	D (30)
Mb-Cart20.1 Melanoma	Miltenyi Biomedicine GmbH	N/A	D (30)
Mb-Cart2019.1 Melanoma	Miltenyi Biomedicine GmbH	N/A	D (30)
Milademetan Melanoma	Rain Oncology Inc	P1/2	D (30)
Incb099280 Melanoma	Incyte Corporation	P1	D (29)
124i-humanized 3f8 Melanoma	Memorial Sloan Kettering Cancer Center	N/A	D (28)
99mTc-nanoscan Melanoma	The Netherlands Cancer Institute	N/A	D (28)
atl001 Melanoma	Achilles Therapeutics UK Limited	P2	D (28)
Glucose, Anhydrous Melanoma	Peter MacCallum Cancer Centre, Australia	N/A	D (28)
Icg-99Mtc-Nanoscan Melanoma	The Netherlands Cancer Institute	N/A	D (28)
Lavender Oil Melanoma	San Gallicano Dermatological Institute IRCCS	N/A	D (28)
Sasanlimab Melanoma	Pfizer	P1	D (28)
124I-cRGDY-PEG-dots Melanoma	Memorial Sloan Kettering Cancer Center	N/A	NR ()
ab821 Melanoma	Yale University	P1	NR ()
avt32-drl_pb Melanoma	Alvotech Swiss AG	P1	NR ()
Bmab1700 Melanoma	Biocon Biologics UK PLC	P1	NR ()
Bmab1800 Melanoma	Biocon Biologics UK PLC	P1	NR ()
Daromun Melanoma	Philogen S.p.A.	P3	NR ()
Fluorescent Crgdy-Peg-Cy5.5-C Dots Melanoma	Memorial Sloan Kettering Cancer Center	P1/2	NR ()
jmt108 Melanoma	Shanghai JMT-Bio Inc.	P1/2	NR ()
nm32-2668 Melanoma	Numab Therapeutics AG	P1	NR ()
Opm-101 Melanoma	Oncodesign Precision Medicine	P1/2	NR ()
Prtx007 Melanoma	Primmune Therapeutics, Inc.	P2	NR ()
Rly-8161 Melanoma	Relay Therapeutics, Inc.	P1	NR ()
TJ271 Melanoma	TJ Biopharma Co., Ltd.	P2	NR ()
Transcon Il-2 Β/Γ Melanoma	Ascendis Pharma Oncology Division A/S	P1/2	NR ()

Showing 401 to 435 of 435 assets

PreviousPage 9 of 9Next